Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences, Inc.

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. 

Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. 

Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. 

Interested in joining our team? Please check out our jobs at
https://cariboubio.bamboohr.com/jobs/

Intellia Therapeutics

Janus Henderson Investors

LifeSci Venture Partners

Maverick Ventures

Heritage Group

Ridgeback Capital

Farallon Capital Management

AbbVie Biotech Ventures

Adage Capital Management

Avego Bioscience Capital

Avidity Partners

Caribou Biosciences

Join our VP, clinical development Socorro Portella, MD, and director of clinical research Ashley Hammad, AG-CNS, tomorrow at the #CRISPR 2.0 workshop, A 101 in First-in-Human CRISPR Trials taking place at 1:00pm ET tomorrow.

Kevin Liao, associate director, supply chain, will lead a workshop at the Donor Selection and Cell Source Summit. Join him on Tuesday, Nov. 28 at 1 pm ET.

The Caribou team will be presenting at the 4th Annual #CRISPR 2.0 Conference next week in Boston! Socorro Portella, MD, and Ashley Hammad, RN, will lead a workshop on Tuesday, Nov. 28 at 1 pm ET and Enrique Zudaire, PhD, will present on Thursday, Nov. 30 at 11:45 am ET. #CRISPR #CARTcell

Members of the Caribou team enjoyed an incredible night celebrating the accomplishments of Paul Donohoue, associate director of platform discovery and co-inventor of Caribou’s chRDNA technology, and the other nine esteemed winners of the 2023 Biocom California Catalyst Awards. Join us, once again, in congratulating Paul on this very well-deserved recognition of his innovation and scientific advancement in #CRISPR genome-editing technologies.  

Want to learn more about one of Paul's inventions? Check it out here: https://lnkd.in/gbEsNexH

Tune in for our company presentation by President and CEO Rachel Haurwitz, PhD, at the Jefferies London Healthcare Conference. A link to the webcast is on the investor section of our website: https://lnkd.in/gjSwyTzc

Caribou would be nothing without the incredible people who make up #theHerd. We are starting a new series to highlight Caribou’s leaders and explore their team’s impact, why they joined Caribou, and what drives them to develop allogeneic CAR-T cell therapies. We start the series with Enrique Zudaire, PhD. Watch the video to learn more about Kike!

Ahead of Veterans Day, we’d like to extend our gratitude to American veterans, especially those who are part of #TheHerd. Thank you for your service. #VeteransDay

This year, we have advanced our programs to build value across the pipeline and position Caribou as a leader in the allogeneic CAR-T cell therapy space. Learn more about our progress in our Q3 2023 financial results here: https://lnkd.in/gcXfDtbf #CRISPR #CARTcelltherapy

We are excited to announce the appointment of Jagannath Sundar, MD, to our scientific advisory board. We welcome Dr. Jagannath and his insights as a renowned expert in the treatment of #multiplemyeloma.
https://lnkd.in/eM47dKkA

Don’t miss Caribou Biosciences at upcoming investor conferences—tune in to available webcasts here: https://lnkd.in/gjSwyTzc

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	5.79M -	12.36M 113.56%	9.60M 22.35%	13.85M 44.31%	34.48M 148.91%
cost of revenue	23.64M -	34.42M 45.65%	984K 97.14%	3.64M 270.02%	3.52M 3.19%
gross profit	-17.85M -	-22.06M 23.63%	8.61M 139.04%	10.21M 18.53%	30.95M 203.15%
selling and marketing expenses					-3.52M -
general and administrative expenses	16.46M -	14.06M 14.57%	24.32M 72.99%	38.02M 56.32%	38.46M 1.16%
selling general and administrative expenses	16.46M -	14.06M 14.57%	24.32M 72.99%	38.02M 56.32%	34.94M 8.11%
research and development expenses	23.64M -	34.42M 45.65%	52.26M 51.79%	82.23M 57.36%	112.08M 36.29%
other expenses		514K -	-1.35M 362.06%	7.18M 633.11%	14.19M 97.58%
cost and expenses	40.09M -	48.48M 20.93%	76.58M 57.94%	120.25M 57.03%	150.54M 25.19%
operating expenses	40.09M -	48.48M 20.93%	76.58M 57.94%	120.25M 57.03%	147.01M 22.25%
interest expense	4K -	20K 400%	8K 60%	-8.54M 106,812.50%
ebitda	-32.51M -	-34.47M 6.05%	-68.18M 97.77%	-106.27M 55.87%	-112.53M 5.90%
operating income	-34.30M -	-36.12M 5.30%	-66.98M 85.41%	-106.40M 58.85%	-116.06M 9.08%
depreciation and amortization	1.80M -	1.65M 8.23%	-1.20M 172.67%	133K 111.09%	3.52M 2,550.38%
total other income expenses net	3.34M -	-3K 100.09%	377K 12,666.67%	7.05M 1,769.50%	14.18M 101.22%
income before tax	-30.97M -	-36.13M 16.66%	-66.60M 84.36%	-99.35M 49.17%	-101.88M 2.54%
income tax expense	-7.54M -	-1.82M 75.87%	321K 117.65%	70K 78.19%	193K 175.71%
net income	-23.43M -	-34.31M 46.42%	-66.92M 95.07%	-99.42M 48.56%	-102.07M 2.66%
weighted average shs out	59.97M -	59.97M 0%	60.26M 0.49%	60.80M 0.89%	73.81M 21.39%
weighted average shs out dil	59.97M -	59.97M 0%	60.26M 0.49%	60.80M 0.89%	73.81M 21.39%
eps	-0.39 -	-0.57 46.15%	-1.11 94.74%	-1.64 47.75%	-1.38 15.85%
epsdiluted	-0.39 -	-0.57 46.15%	-1.11 94.74%	-1.64 47.75%	-1.38 15.85%

COM:CARIBOUBIO

Caribou Biosciences

Last Close

2.11

30/08 20:00

Market Cap

153.54M

Beta: -

Volume Today

566.68K

Avg: -

Preview